UC Davis researchers discover genetic switch involved in cells' response to radiation therapyNovember 17, 2005Finding could lead to more effective, less toxic radiosensitizing drugs for cancer patients UC Davis Cancer Center researchers have discovered a genetic switch that causes cancer cells to become more sensitive to a drug administered to enhance radiation therapy effectiveness. The switch does not make the drug more toxic. The discovery may help scientists design new anti-cancer agents that enhance the effectiveness of radiation therapy with less toxicity than currently available radiosensitizing drugs. The finding is reported in the Priority Reports section of the last issue of the journal Cancer Research (Oct. 17 - Oct. 31). Allan Chen, assistant professor of radiation oncology at UC Davis Cancer Center, found that Ku86, a gene involved in DNA repair, acts as a switch that, when turned off, makes cells significantly more vulnerable to the radiosensitizing property of the anti-cancer drug camptothecin. Ku86 had no effect on the radiosensitizing abilities of other anti-cancer agents tested - etoposide, cisplatin and vinblastine. Ku86 also had no effect on camptothecin toxicity. The team concluded that, like a switch that controls only a certain light bulb, Ku86 uniquely affects radiosensitization, but not cytotoxicity, induced by camptothecin. The UC Davis researchers started by identifying which enzymes affect radiosensitivity and cytotoxicity, then painstakingly determined a way to control such enzymes. The investigation focused on an enzyme called DNA topoisomerase I, which is responsible for cutting single DNA strands so that the DNA molecule can rotate and unwind during transcription and replication. Camptothecin stops DNA topoisomerase I during the unwinding process, ultimately killing the cell. University of California, Davis-Health System |
|||||||||||||||||||||
| Related Radiation Therapy Current Events and Radiation Therapy News Articles Rare pancreatic cancer patients may live longer when treated with radiation therapy Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy. New cancer target for non-Hodgkin's lymphoma Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. Iowa State engineers develop 3-D software to give doctors, students a view inside the body James Oliver picked up an Xbox game controller, looked up to a video screen and used the device's buttons and joystick to fly through a patient's chest cavity for an up-close look at the bottom of the heart. Men leave: Separation and divorce far more common when the wife is the patient A woman is six times more likely to be separated or divorced soon after a diagnosis of cancer or multiple sclerosis than if a man in the relationship is the patient, according to a study that examined the role gender played in so-called "partner abandonment." The study also found that the longer the marriage the more likely it would remain intact. PET imaging response a prognostic factor after thoracic radiation therapy for lung cancer A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting. Chemo-radiation before prostate removal may prevent cancer recurrence Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival. Radiation therapy technique successfully treats pain in patients with advanced cancer Stereotactic radiosurgery (SRS), a radiation therapy procedure pioneered at the University of Pittsburgh Cancer Institute (UPCI) that precisely delivers a large dose of radiation to tumors, effectively controls pain in patients with cancer that has spread to the spine. Aiming to avoid damage to neurocognitive areas of the brain during cranial radiation Radiation oncologists at Rush University Medical Center are intent on finding ways to avoid damage to the critically important hippocampus and limbic circuit of the brain when cranial radiation is required to treat existing or potential metastatic cancers. Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results. Stereotactic radiotherapy offers noninvasive, effective treatment for frail patients with early-stage lung cancer Stereotactic body radiation therapy (SBRT) should be considered a new standard of care for early-stage lung cancer treatment in patients with co-existing medical problems, according to results from a national clinical trial led by UT Southwestern Medical Center physicians. More Radiation Therapy Current Events and Radiation Therapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||